

QUESTIONS PURSUANT TO RULE 11 OF THE RULES OF PROCEDURE

From	Deputy P.J. Roffey
To	Committee <i>for</i> Health & Social Care
Subject	Access to NICE approved drugs
Date of questions	15 th February, 2018
States' Meeting	28 th February, 2018

Question 1

Given that the National Institute for Clinical Excellence has far more expertise and experience in assessing the efficacy and cost effectiveness of drugs, and drug treatment regimes, than anybody in Guernsey why are Guernsey patients with serious or life threatening conditions being denied access to drugs which are NICE approved and available on the NHS?

Question 2

Is it correct that the Committee for Health & Social Care's advisory body on the funding of prescription drugs has a guideline that no drug can even be considered if the cost per Quality Adjusted Life Year exceeds £30,000?

Question 3

While there is an obvious budgetary need to restrict free access to new and very expensive drugs would the president not agree that if the Committee for Health & Social Care is saying its funding situation is worse than that of the NHS then the States should be deeply concerned over that situation?

Question 4

Conversely if its funding situation is not worse then why is Guernsey being more restrictive than the NHS over access to drugs for those patients with the most serious, life threatening, conditions?

Question 5

Would the President agree with me that Guernsey patients who are denied funding for cancer drugs in Guernsey are in a far worse situation than their counterparts in the UK both because it is very much harder to become involved in clinical trials for emerging drugs and because they have no access to the Cancer Drug Fund.

Question 6

Would the Committee for Health & Social Care please agree to an urgent review of the local criteria for publically funded access to drugs for treating serious, life threatening, conditions so that local patients are treated at least as favourably as they would be if they were resident in the UK?